180 related articles for article (PubMed ID: 34724153)
1. Vedolizumab therapy for pediatric steroid-refractory gastrointestinal acute graft-versus-host disease.
Isshiki K; Kamiya T; Endo A; Okamoto K; Osumi T; Kawai T; Arai K; Tomizawa D; Ohtsuka K; Nagahori M; Imai K; Kato M; Kanegane H
Int J Hematol; 2022 Apr; 115(4):590-594. PubMed ID: 34724153
[TBL] [Abstract][Full Text] [Related]
2. Vedolizumab in highly resistant acute gastrointestinal graft-versus-host disease after allogeneic stem cell transplantation: A single-center pediatric series.
Rosa M; Jarmoliński T; Miśkiewicz-Migoń I; Liszka K; Miśkiewicz-Bujna J; Panasiuk A; Frączkiewicz J; Ussowicz M
Adv Clin Exp Med; 2022 Mar; 31(3):345-350. PubMed ID: 35212198
[TBL] [Abstract][Full Text] [Related]
3. Vedolizumab for pediatric patients with gastrointestinal acute graft-versus-host-disease.
Aldouby Bier G; Zaidman I; Dinur Schejter Y; NaserEddin A; Stepensky P; Even-Or E
Pediatr Blood Cancer; 2023 Jan; 70(1):e30061. PubMed ID: 36326084
[TBL] [Abstract][Full Text] [Related]
4. Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review.
Fløisand Y; Lazarevic VL; Maertens J; Mattsson J; Shah NN; Zachée P; Taylor A; Akbari M; Quadri S; Parfionovas A; Chen YB
Biol Blood Marrow Transplant; 2019 Apr; 25(4):720-727. PubMed ID: 30468919
[TBL] [Abstract][Full Text] [Related]
5. Vedolizumab for children with intestinal graft-versus-host disease: a case report and literature review.
Fukuta T; Muramatsu H; Yamashita D; Sajiki D; Maemura R; Tsumura Y; Yamamori A; Imaya M; Wakamatsu M; Nishikawa E; Narita K; Kataoka S; Taniguchi R; Narita A; Nishio N; Takahashi Y
Int J Hematol; 2023 Sep; 118(3):411-417. PubMed ID: 37074509
[TBL] [Abstract][Full Text] [Related]
6. [Steroid-refractory gastrointestinal acute graft-versus-host disease treated with vedolizumab and ruxolitinib in a pediatric patient with therapy-related acute myeloid leukemia].
Nagasawa S; Yamada A; Kinoshita M; Kamimura S; Tanaka H; Nishikawa T; Okamoto Y; Moritake H
Rinsho Ketsueki; 2023; 64(1):23-29. PubMed ID: 36775302
[TBL] [Abstract][Full Text] [Related]
7. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease.
Mehta RS; Saliba RM; Jan A; Shigle TL; Wang E; Nieto Y; Ciurea SO; Oran B; Im J; Olson A; Marin D; Qazilbash M; Khouri I; Rondon G; Anderlini P; Rezvani K; Popat U; Kebriaei P; Shpall E; Champlin R; Alousi A
Transplant Cell Ther; 2021 Mar; 27(3):272.e1-272.e5. PubMed ID: 33781539
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of children treated with daclizumab for steroid-refractory gastrointestinal GvHD in a prospective study.
Hamidieh AA; Hadjibabaie M; Ghehi MT; Jalili M; Hosseini A; Pasha F; Behfar M; Ghavamzadeh A
Pediatr Transplant; 2012 Sep; 16(6):664-9. PubMed ID: 22738324
[TBL] [Abstract][Full Text] [Related]
9. Vedolizumab for acute gastrointestinal graft-versus-host disease: A systematic review and meta-analysis.
Li AC; Dong C; Tay ST; Ananthakrishnan A; Ma KS
Front Immunol; 2022; 13():1025350. PubMed ID: 36439135
[TBL] [Abstract][Full Text] [Related]
10. Pathophysiology of gastrointestinal acute graft-versus-host disease and the potential role of glucagon-like peptide 2.
Zeiser R; Chen YB; Youssef NN; Ayuk F
Br J Haematol; 2023 May; 201(4):620-627. PubMed ID: 36965050
[TBL] [Abstract][Full Text] [Related]
11. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
[TBL] [Abstract][Full Text] [Related]
12. α4β7 Integrin expression and blockade in pediatric and young adult gastrointestinal graft-versus-host disease.
Ibrahimova A; Davies SM; Lane A; Jordan MB; Lake K; Litts B; Chaturvedi V; Owsley E; Myers KC; Nelson AS; Mehta PA; Marsh RA; Khandelwal P
Pediatr Blood Cancer; 2021 Aug; 68(8):e28968. PubMed ID: 33861521
[TBL] [Abstract][Full Text] [Related]
13. Anti-α4β7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease.
Danylesko I; Bukauskas A; Paulson M; Peceliunas V; Gedde-Dahl D Y T; Shimoni A; Shouval R; Griskevicius L; Floisand Y; Nagler A
Bone Marrow Transplant; 2019 Jul; 54(7):987-993. PubMed ID: 30356163
[TBL] [Abstract][Full Text] [Related]
14. Targeting Integrin α4β7 in Steroid-Refractory Intestinal Graft-versus-Host Disease.
Fløisand Y; Lundin KEA; Lazarevic V; Kristiansen JD; Osnes LTN; Tjønnfjord GE; Reims HM; Gedde-Dahl T
Biol Blood Marrow Transplant; 2017 Jan; 23(1):172-175. PubMed ID: 27777142
[TBL] [Abstract][Full Text] [Related]
15. A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease.
Fløisand Y; Schroeder MA; Chevallier P; Selleslag D; Devine S; Renteria AS; Mohty M; Yakoub-Agha I; Chen C; Parfionovas A; Quadri S; Jansson J; Akbari M; Chen YB
Bone Marrow Transplant; 2021 Oct; 56(10):2477-2488. PubMed ID: 34108672
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
Chen X; Wang C; Yin J; Xu J; Wei J; Zhang Y
PLoS One; 2015; 10(8):e0136991. PubMed ID: 26323092
[TBL] [Abstract][Full Text] [Related]
17. Infliximab for steroid refractory or dependent gastrointestinal acute graft-versus-host disease in children after allogeneic hematopoietic stem cell transplantation.
Yang J; Cheuk DK; Ha SY; Chiang AK; Lee TL; Ho MH; Chan GC
Pediatr Transplant; 2012 Nov; 16(7):771-8. PubMed ID: 22905718
[TBL] [Abstract][Full Text] [Related]
18. Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Chen YB; Shah NN; Renteria AS; Cutler C; Jansson J; Akbari M; Chen C; Quadri S; Parfionovas A; Devine SM
Blood Adv; 2019 Dec; 3(23):4136-4146. PubMed ID: 31821456
[TBL] [Abstract][Full Text] [Related]
19. Multi-parametric MRI in the diagnosis and scoring of gastrointestinal acute graft-versus-host disease.
Maccioni F; La Rocca U; Milanese A; Busato L; Cleri A; Lopez M; Manganaro L; De Felice C; Di Gioia C; Vestri AR; Catalano C; Iori AP
Eur Radiol; 2023 Sep; 33(9):5911-5923. PubMed ID: 37071163
[TBL] [Abstract][Full Text] [Related]
20. Acute gastrointestinal graft-versus-host disease in pediatric patients: serum albumin on day 5 from initiation of therapy correlates with nonrelapse mortality and overall survival.
Goussetis E; Paisiou A; Kitra V; Peristeri I; Vessalas G; Stefanaki K; Panayotou I; Giamaiou K; Kontou E; Kitzoni M; Dimopoulou MN; Karkelis S; Kafritsa Y; Rapsomaniki E; Papassotiriou I; Tsirigotis P; Roma E; Graphakos S
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1058-66. PubMed ID: 21073975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
